Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Scotland

Living with RA Report

Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

Research Partnership

- PMLiVE

Stem cell therapy promising for rheumatoid arthritis

Mesoblast’s phase II trial sees "impressive efficacy" in refractory patients

- PMLiVE

GSK plans sirukumab filing in rheumatoid arthritis next year

Says phase III trials showed 'no unexpected safety findings'

- PMLiVE

Amgen’s biosimilar shows clinical equivalence with Humira

ABP 501 as effective as AbbVie's blockbuster in phase III rheumatoid arthritis trial

- PMLiVE

Lilly’s baricitinib beats Humira in trial for RA

Posts positive phase III data against the world's biggest-selling drug

National Institute for Health and Care Excellence NICE logo

NICE set to recommend seven biologics for severe rheumatoid arthritis

List includes Roche's RoActemra and biosimilars Inflectra and Remsima

- PMLiVE

India denies patent on Pfizer’s Xeljanz

Drug deemed not an invention because it is not more effective than original compound

Infographic: RA Perceptions

HCPs predict the future of the biologics market

Research Partnership

Infographic: RA market snapshot

An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...

Research Partnership

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

- PMLiVE

Cancer drugs lead SMC recommendations

New treatments from Roche, Lilly and Celgene backed for use in Scotland

- PMLiVE

SMC fails to recommend Roche’s Perjeta

Says drug is not a cost-effective option in breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links